Press Release Details

Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage

PALO ALTO, Calif., April 4, 2016 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc, (NASDAQ:  EIGR) announced today that its Board of Directors has appointed Charles J. "Chuck" Bramlage as a member of the Board.

Eiger BioPharmaceuticals (PRNewsFoto/Eiger BioPharmaceuticals, Inc.)

Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing, sales, and corporate operations spanning large pharma to start up pharma.  He is currently the Chief Executive Officer of Pearl Therapeutics, Inc., a development stage start-up company focused on treatments for respiratory diseases that was acquired by AstraZeneca.  He previously served as President of Pharmaceutical Products at Covidien plc and President of European Operations at Valeant Pharmaceuticals International, Inc.  Earlier in his career, Mr. Bramlage held senior level U.S and International commercial operating positions at GlaxoSmithKline plc and Merck & Company, Inc.  Mr. Bramlage and his teams have launched over 40 prescription brands across 14 therapeutic areas.

"We enthusiastically welcome Chuck to our Board of Directors and look forward to benefiting from his background and experience as we begin to direct product development toward maximizing market opportunities for each pipeline program," said Tom Dietz, Ph.D., Eiger's Chairman of the Board.

David Cory, President and Chief Executive Officer of Eiger, stated, "Chuck brings a wealth of experience in global commercial strategy and operations.  He will provide valuable insight as we begin to consider commercial opportunities and market development for each of our multiple, diverse clinical stage programs."

About Eiger

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases.  The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Investors: Jim Shaffer, Eiger BioPharmaceuticals, Inc., 919-345-4256, [email protected]

Logo -

To view the original version on PR Newswire, visit:

SOURCE Eiger BioPharmaceuticals, Inc.